Kirk L. Pappan

G1 Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

38h-index4.0kcitations97works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Metabolomics and Mass Spectrometry Studies(21), Diet and metabolism studies(16), Pancreatic function and diabetes(14), Bladder and Urothelial Cancer Treatments(13), Fibroblast Growth Factor Research(13)

Publications97 total

Supplementary Data Tables 1 from Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
2024Open Access
Supplementary Table Names 1 from Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
2024Open Access
Figure S5 from Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
2024Open Access
Figure S2 from Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
2024Open Access
Figure S6 from Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
2024Open Access
Data from Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
2024Open Access
Supplementary Methods 1 from Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
2024Open Access
Figure S3 from Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
2024Open Access
Supplementary Table Legend 1 from Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
2024Open Access
Figure S4 from Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
2024Open Access
Figure S1 from Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
2024Open Access
Characterization of FGFR Alterations and Activation in Patients with High-Risk Non–Muscle-Invasive Bladder Cancer
Clinical Cancer Research·2024· 4 citedOpen Access
Abstract 1040: Development of a novel RNA-based microsatellite stable predictive response signature (MSS-PRS) to identify MSS colorectal cancer (CRC) patients with a microsatellite instability-high (MSI-H) molecular phenotype
Cancer Research·2024
Detection of <i>Clostridioides difficile</i> infection by assessment of exhaled breath volatile organic compounds
Journal of Breath Research·2024· 2 citedOpen Access
Development of a novel RNA-based fibroblast growth factor receptor response signature (FGFR-PRS) for use in patients with urothelial cancer (UC).
Journal of Clinical Oncology·2024
P16-040-23 Dietary DHA Supports Glucose Use by Muscle in Association With Improved Endocannabinoid System Gene Expression in C57bl/6 Mice
Current Developments in Nutrition·2023Open Access
Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breath
Critical Reviews in Clinical Laboratory Sciences·2022· 75 citedOpen Access
Long-Chain Acylcholines Link Butyrylcholinesterase to Regulation of Non-neuronal Cholinergic Signaling
Journal of Proteome Research·2021· 17 cited
Comparison of Untargeted Metabolomic Profiling vs Traditional Metabolic Screening to Identify Inborn Errors of Metabolism
JAMA Network Open·2021· 70 citedOpen Access
The SARS-CoV-2 viral load in COVID-19 patients is lower on face mask filters than on nasopharyngeal swabs
Scientific Reports·2021· 14 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Adam D. Kennedy(8), Sarah H. Elsea(8), Connie A. Marshall(8), Michael L. McDaniel(8), Xuemin Wang(7), John C. Reese(6), Gerald R. Reeck(6), Guim Kwon(6), David C. Nieman(6), Navdeep S. Mutti(5), Qin Sun(5), Anne M. Evans(4), Jacob Wulff(4), V. Reid Sutton(4), Luke A. D. Miller(3), Marı́a S. Remedi(3), Nicholas D. Gillitt(3), R. Andrew Shanely(3), Mary Pat Meaney(3), Trey Coleman(3)